Establishment Labs Holdings Inc. (ESTA) Earnings Call Transcript & Summary

October 29, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 43 min

Earnings Call Speaker Segments

Malavika William

executive
#1

Thanks, operator, and thanks to all of you for being with us today. Joining me are Peter Caldini, our Chief Executive Officer, and Sandra Harris, our Chief Financial Officer. Once our prepared remarks are done, we'll open things up for your questions. Before we get started, I want to note that remarks from management on this call will contain forward-looking statements as defined under federal securities law. Among these are statements regarding Establishment Labs's financial outlook and the company's plans and timing for product development and sales. Such forward-looking statements rest on management's current expectations and carry risks and uncertainties; for a discussion of the main risk factors and uncertainties that could affect our performance or make actual results differ materially from these statements, I'd encourage you to review our latest annual and quarterly reports on Form 10-K and Form 10-Q, along with other SEC filings, all of which are available on our website at establishmentlabs.com. I'd also note that our comments may include certain non-GAAP financial measures relating to our performance, including but not limited to sales results, which may be stated on a constant currency basis, or EBITDA, which we disclose on an adjusted EBITDA basis. Reconciliations of non-GAAP measures to comparable GAAP financial measures, where available, can be found in today's press release, which is posted on our website. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, October 29th, 2026. Except as required by law, Establishment Labs assumes no obligation to revise or otherwise update any statement to reflect events or circumstances occurring after the date of this call. With that, I'm pleased to hand the call over to Peter.

Peter Caldini

executive
#2

Hello everyone, and thank you for joining us. Establishment Labs had another strong quarter in Q3, gaining market share and expanding the breast aesthetics category through innovation. Third-quarter revenue reached $72 million, a 33.9% increase over the prior-year period, driven by share gains in the U.S. and growth across our OUS business. Adjusted EBITDA climbed to $6.4 million versus $1.2 million a year earlier, representing an 8.9% adjusted EBITDA margin and reflecting improved operating leverage as we scale. Q3 is our first quarter with positive free cash flow — a major milestone — and we look forward to 2027 being our first full year of positive free cash flow. Our U.S. business brought in $26 million in revenue, a 119% year-over-year increase. Revenue from outside the United States grew 9.7% to $46 million. Growth came from both businesses, which shows momentum across our global operations. Our minimally invasive platform is a key growth driver, bringing in roughly $9 million of third quarter revenue, up 124% year-over-year, propelled by our U.S. expansion. On a sequential basis, revenue was lower, which reflects the usual summer seasonality in our OUS direct markets. Minimally invasive made up roughly 15% of revenue so far this year, and the U.S. generated close to 50% of platform revenue in Q3, which shows adoption is rising. For the full year, we now anticipate minimally invasive revenue will exceed $40 million, compared with our prior guidance of more than $35 million. Q3 brought a key financial milestone: we generated positive free cash flow for the first time in the company's history. Operating cash flow came in at $7.7 million, and free cash flow was $5.1 million. That's a major accomplishment, particularly as we continue putting money into our U.S. expansion and innovation pipeline. This demonstrates that our financial model is growing more scalable and that we're able to convert top-line growth into cash. The results we posted in Q3 stand out particularly when you consider how our industry has traditionally been seasonal, with the third quarter usually the weakest of the year. We've gotten off to a strong start in Q4, and that supports our decision to lift the full-year 2026 revenue outlook to over $274 million, compared with the earlier guidance of $269 million-$271 million. Momentum is strong in both our U.S. and OUS operations, and we see room for further expansion. The wins we're seeing in 2026 ought to extend into 2027, and we're anticipating 25% revenue growth in that year. Turning to the United States, we closed out the quarter with 2,100 accounts. We continue to bring on new accounts on a regular basis, but more and more of our attention is going to utilization inside the base we already have. We've made considerable headway in establishing Motiva in the U.S. market, including with a large number of the highest volume breast augmentation surgeons. Now that this foundation is in place, we're turning our focus toward capturing a larger share of their business. A recent industry survey backs up this opportunity. For surgeons who say they use Motiva, it represented an average of 43% of their implant procedures, which underscores both the adoption we've achieved and the runway for further growth. The standout metric is retention: 85% of accounts that bought Motiva during Q2 placed another order in Q3. That signals plastic surgeons are doing more than trying Motiva implants — they're weaving them into their practices. This October brought FDA clearance for additional Motiva sizes, and we expect to launch those commercially before the year is out, which will give surgeons a broader range of options for patients. Industry data leaves something to be desired in terms of reporting quality, but our own estimates put Motiva at about a 30% share of the U.S. augmentation market as of the end of September. Reaching that level in just two years represents meaningful progress. Figures from the American Society of Plastic Surgeons indicate that U.S. Between 2024 and 2025, breast augmentation procedures increased 11%, following a stretch of several years during which growth in that category stayed fairly modest. Both Motiva implants and Preservé are plainly playing a part in drawing renewed interest to the category, together with other market forces. Our approach is not simply about taking market share; it is about expanding the market through innovation and broadening the pool of patients who consider the category. Preservé represented roughly 17% of our U.S. revenue during the quarter, and by the close of the quarter over 400 surgeons had completed training. Demand for training remains strong, and we anticipate 500 surgeons trained by year-end. Just like with our main Motiva implant segment, we're now focusing on increasing usage among plastic surgeons already trained on Preservé, which opens up more growth opportunities inside our current surgeon base. Feedback from surgeons helps us understand adoption better. In a survey involving 78 surgeons trained on Preservé, those who responded indicated that about 22% of their breast augmentation cases had transitioned to Preservé. 95% said they were satisfied or very satisfied. Additionally, 88% noted that Preservé had brought in patients who hadn't been thinking about augmentation before, and 98% mentioned patients asking for Preservé specifically by name. These survey findings match the adoption patterns we're seeing. Let me give two examples that show what's happening in the market. A surgeon practicing in the Northeast said that 89% of her primary breast augmentation patients have picked the procedure since Preservé came out. A second plastic surgeon — who had Preservé done on herself — said that, as a young mom and working surgeon, she would not have contemplated breast augmentation after having kids if this option weren't available. Following her procedure, she was able to fly two days later, returned to operating three days later, and made it to a major conference before that same week was over; those examples illustrate not just how Preservé is winning adoption inside existing practices, but also the potential it holds for drawing new patients into the breast augmentation market. Consumer awareness keeps growing. This quarter, Preservé earned an Allure Best of Beauty Breakthrough award. Forbes also ran a piece on it, which framed Preservé as the Rolls Royce of breast augmentation. Recognition like this strengthens how aware surgeons and consumers are becoming of Preservé. Revenue outside the United States rose 9.7% compared with a year earlier, reaching $46 million, and both our direct and distributor markets contributed to that gain. In our direct markets, growth for the quarter was 16% year-over-year, with especially solid results throughout Europe. Growth was broad-based, and Italy, the U.K., and Germany ranked among the largest contributors. Sequentially, those markets showed the summer seasonality we typically see; the investments we've made in the direct businesses are paying off, including stronger leadership, greater commercial focus, and a rising contribution from our minimally invasive platform. Distributors also delivered a solid performance, helped considerably by Asia Pacific. During the quarter, distributor-led markets made up about 60% of our revenue outside the U.S., versus the 50% we had anticipated — a reflection of the way order timing fluctuates in those regions. Looking ahead, we see potential in both channels, supported by the direct presence we have built in our markets, our distributor partnerships, and rising uptake of our minimally invasive platform. All of that provides several paths to lasting OUS growth. Minimally invasive plays a growing role in our OUS growth strategy, and within it we are seeing wide adoption of Preservé and Mia. Revenue from minimally invasive products outside the U.S. rose 16% compared with the prior year in the quarter. What we're seeing suggests that minimally invasive procedures are turning into a significant gateway into the Motiva ecosystem. In Europe this quarter, close to 50% of new accounts got their start through minimally invasive. Meanwhile, we're also growing inside our current customer base, since long-standing accounts are taking up minimally invasive too.

Peter Caldini

executive
#3

Mia and Preservé are doing more than just adding incremental sales within our current customer base. Increasingly, they are pulling new surgeons and practices toward Establishment Labs, while also generating substantial growth inside accounts we already serve. With the recent U.S. FDA clearance of additional Motiva implant sizes—some as small as 105 cc—surgeons and patients now have a broader range of options to select from. The rising ballerina or yoga breast trend shows growing demand for smaller, more natural-looking outcomes. That approval expands the choices available to women pursuing a more subtle aesthetic, and it represents a significant move toward extending our minimally invasive platform across the United States. We also shared plans to broaden the size offerings for Mia and Preservé worldwide. So Mia is now able to handle sizes as large as 300 cc, while Preservé can go up to 380 cc—which means more patients can choose a minimally invasive breast augmentation. We also recently made public a deal with NuSil, one of our strategic suppliers, and that's another key development. Through this agreement, the basis of our long-term silicone supply relationship becomes stronger, and it helps us scale production. The way pricing works is tied to volume commitments, and adjustments typically track inflation. This represents one more significant move toward putting Establishment Labs in position for sustained growth. As we get ready for the FDA approval we expect for Motiva implants in reconstruction, we're developing the commercial infrastructure and hospital relationships through our Motiva Flora tissue expander. Motiva Flora is now offered at over 350 facilities across the country, which represents a 14% rise for the quarter. Our reconstruction submission continues to move forward. We have answered the FDA's latest information request, and BIMO inspections have been conducted at several clinical sites, the sponsor site included, as part of the review; such inspections are a standard component of the approval process and ought to signal that an approval is getting close; we are assessing regulatory pathways for our Ergonomix2, Mia, and GEM products in our largest markets. In time, wider availability of our portfolio will generate additional growth opportunities. With that, I'll hand the call to Sandra so she can walk through our financial results in greater detail.

Sandra Harris

executive
#4

Thanks, Peter. The financial results for our third quarter show revenue growth and better adjusted profitability as we scale the business. Quarterly revenue came in at $72 million, up 33.9% from $53.8 million in the same period last year, with growth in both our U.S. and OUS businesses; in the United States, revenue rose 119% to $26 million, which was 36.1% of total revenue, versus 22.1% a year ago. Outside the United States, revenue grew 9.7% to $46 million. Now on gross margin. GAAP gross profit was $49.7 million, a gross margin of 69.1%, compared with 70.1% in the prior year quarter. If you set aside $1.3 million in inventory charges tied to restructuring, adjusted gross margin came in at 70.8%. That's a 70 basis point gain compared with a year ago, and it came from a favorable mix in the U.S. and in minimally invasive products. On a sequential basis, adjusted gross margin also went up, helped by continued expansion in the U.S. and the minimally invasive platform, though that gain was partly offset by a larger share of OUS distributor sales, which made up roughly 60% of OUS revenue versus the 50% we had planned. Turning to operating expenses: GAAP operating expenses were $52.3 million, versus $41.7 million in the same period last year. Third quarter operating expenses included litigation-related costs, restructuring and transition activities, and other items that we strip out of certain adjusted measures; you can find those exclusions detailed in our non-GAAP reconciliations. Once you strip those items out, adjusted operating expenses came to $49.6 million, which works out to 68.8% of revenue, versus 77.6% in the same period last year. That gives us 880 basis points of operating expense leverage. Under GAAP, EBITDA showed a loss of $0.9 million, against a loss of $2.2 million a year earlier. Adjusted EBITDA rose to $6.4 million, up from $1.2 million in the prior-year quarter. Adjusted EBITDA margin widened to 8.9%, compared with 2.2% a year ago. The results show we can turn revenue into better adjusted profitability. We're still committed to spending on commercial expansion while creating an operation model that's efficient and scalable. On a GAAP basis, our preliminary net loss came to $10.7 million, or $0.35 per share, versus a net loss of $11.1 million, or $0.38 per share, in the same period last year. Turning to cash flow and the balance sheet: during the third quarter we produced $7.7 million in operating cash flow and $5.1 million in free cash flow, which is the first quarter of positive free cash flow in the company's history. That milestone speaks to strong revenue growth, better profitability, and our ongoing attention to managing working capital. We finished the quarter holding $75.8 million in cash and cash equivalents. Beyond that, the payment-in-kind interest provision in our refinanced debt facility delivers over $5 million in quarterly cash interest savings through the initial PIK period, which gives us extra flexibility to speed up our U.S. expansion and put more into our innovation pipeline. Going forward, we're staying focused on keeping cash generation positive while taking a disciplined approach to working capital and strategic investments that back long-term growth. Now turning to our outlook. As Peter mentioned, for the full year 2026 we're now expecting revenue above $274 million, compared with the $269 million-$271 million range we guided to previously. Adjusted gross margin for the whole year ought to come in around 70.7%, matching what we've done year to date; that reflects OUS distributor sales running hotter than we anticipated, which bring in extra revenue and gross profit dollars even though the margin percentage is lower than on our direct business. Our adjusted operating expense outlook for the full year stays where it was, at $195 million-$200 million. With this updated guidance, we still expect positive adjusted EBITDA for the full year, which speaks to the operating leverage building in the business as revenue climbs. In Q3 we achieved positive free cash flow for the first time in a quarter, and our aim is to sustain that momentum and produce positive free cash flow in fiscal 2027; for 2027 we anticipate 25% growth, fueled by increasing utilization across the United States, broader uptake of our minimally invasive platform, and opportunities throughout our OUS business. With that said, I'll return the floor to Peter for his closing remarks.

Peter Caldini

executive
#5

Thanks, Sandra. The third quarter mattered a great deal for Establishment Labs, and it shows the strides we're making in virtually every area of our operations. It has long been our conviction that innovation widens this category, and we're watching that play out in the U.S. as well as in our OUS markets. Growth can come at us from several directions, and we're constructing a financial model that scales very effectively. Looking ahead to 2027, we see substantial chances to extend the gains of this year. Higher utilization throughout our U.S. account base, wider uptake of our minimally invasive platform, and the possibility of moving into reconstruction together offer a number of routes to growth; the opportunities in front of us encourage us, and we stay concentrated on execution and on enhancing financial performance. Operator, we're ready now for questions.

Mike Matson

analyst
#6

Yes, thank you for taking my questions. I suppose I wanted to begin with the international markets. I think there had been a bit of concern perhaps among investors regarding the outlook there, with everything happening from a macro standpoint. Clearly, 10% is really solid growth, but I'm just wondering what you're seeing when it comes to market performance for breast implants outside the U.S. Have you noticed any kind of slowdown in market growth, and maybe Establishment is simply outperforming, or are those markets genuinely healthy?

Peter Caldini

executive
#7

Yes, thanks Mike. When it comes to the OUS markets, I would say that in terms of overall market performance, the regions have been fairly stable, right? With a few exceptions, of course, the Middle East being one of them, given the ongoing conflict, and that clearly has had an effect on the market. It has also affected our performance in that region. We are receiving orders for the Middle East, but it is clearly not at the level we have historically had. But overall, the markets are quite stable, and as for our focus, we are very pleased with the performance we have delivered in OUS markets. A major focus for us was on the direct markets, and once again we had 16% growth this quarter; this is something like our sixth quarter of double-digit growth in our direct markets, and that has been a priority for us. We've optimized our leadership team, put more resources into those markets, and we've also really changed how we've operated the relationships with our distributor markets. The trends are very strong. We're well-positioned to finish the year, and that is really going to continue into 2027.

Allen Gong

analyst
#8

Thanks for taking the question, and nice work on the strong quarter. I wanted to begin with something about minimally invasive. We're clearly seeing robust growth compared with a year ago; but looking at the first and second quarters, we went from $9 million in the first quarter up to roughly $12 million in the second quarter. So it appears to be stepping back in the third quarter. Is that simply normal seasonality? Or is it because the market may be somewhat more sensitive to pricier products? Help me understand what's driving that.

Peter Caldini

executive
#9

Yeah. Thanks, Allen. Seasonality is really what's driving it. Much of our minimally invasive business outside the U.S. sits in our direct European markets. Q3, as you're aware, is a notably soft season, which affected procedure volumes — not only for minimally invasive but across the board. That weighed on the quarter-over-quarter comparison. Against the prior year, though, those markets posted substantial growth. The softness really comes down to seasonality alone.

Sandra Harris

executive
#10

Allen, just to remind everyone, we've also lifted our minimally invasive target to more than $40 million.

Analyst

analyst
#11

Hello, Colin here filling in for Josh. Thanks for taking my question. You've all observed considerable momentum when it comes to adding accounts in the U.S. I was wondering if you could discuss your plans for pushing that 43% Motiva utilization upward among people who already use it, and perhaps how much chance there is to reach additional doctors within practices where you already have a presence. Thank you.

Peter Caldini

executive
#12

Yes. Thanks, Colin; we've felt really good about the penetration achieved regarding account count, and we sit at more than 2,100 accounts. Yet as you pointed out, at present it comes down to utilization. We're advancing nicely on that front. That has been a priority for us. Much of it is honestly just a function of the usual scheduling cadence. After you land an account, some time may pass before they begin using it, depending on schedules; plus they need to get comfortable since Motiva behaves somewhat differently from what they're used to. But from a sales perspective, from the sales force perspective, our marketing efforts are likewise sharply aimed at lifting that utilization. And we are noticing the payoff. On a month-over-month basis, average orders per account keep climbing, and that signals clearly that we're raising utilization, and that 43%, as you noted, we anticipate will rise. We view that as solid traction, yet there's also ample headroom for us to expand.

Matt Taylor

analyst
#13

Morning, and thanks for taking my question. Congratulations on a solid quarter and on producing some free cash flow. So I wanted to ask — you mentioned 25% growth in 2027. Could you give us any color on how we should think about margins or cash flow for next year as we update our models?

Sandra Harris

executive
#14

Yeah, absolutely, Matt. Looking ahead to next year, we've set an expectation of 25% revenue growth, and the growth of our U.S. business and that minimally invasive platform both support that; we also view those as opportunities for further gross margin expansion. With the U.S. growing beyond 35% of our revenue and our minimally invasive exceeding 15%, we still believe 50 to 100 basis points is a reasonable improvement in our gross margin based just on that geographical mix. Ultimately, we believe the 50 to 100 basis points for FY 2027, and that will depend somewhat on geographic and channel mix.

Sam Eiber

analyst
#15

Hello, and good morning. I appreciate you taking my questions. Perhaps we could revisit the push to boost utilization across those 2,100 existing accounts. Could you walk me through some of the investments required — whether that means the commercial team or any direct-to-consumer efforts you'll really be concentrating on to lift that figure?

Peter Caldini

executive
#16

Yes, thank you. Thanks, Sam. As I said, some of it is simply the natural progression that follows once an account is landed, as they move through their schedules and as they begin using it and gain some experience with it. On the investment side, it's really about growing our sales force. We've raised the rep count to 55; we've also brought in extra leadership positions. A large piece of that involves targeting and making sure we drive utilization up. Marketing activities will be what we've done previously. We're able to make more targeted investments in particular accounts, and that's something we've done before, and I believe it's something we'll keep doing going forward. Those are the sorts of levers we're pulling to enhance utilization, and we're already seeing the effect so far.

Joe Federico

analyst
#17

Hello, everyone, and thank you for taking the question. I want to zoom in a little more on the gross margin we saw this quarter — I understand geography played a role, given how strong international sales were and the distributor markets within that — but as I look across the year, with guidance moving lower, I'm trying to understand how that carries into the fourth-quarter margin, particularly because implied revenue isn't really shifting much. Is the margin there also shaped by mix effects from international, with total sales maybe running above what's currently estimated? And what would that mean for the U.S.? Some clarity on those pieces would be useful. Thank you.

Sandra Harris

executive
#18

Yeah. Sam, for the third quarter our adjusted gross margin was 70.8%. That's up 70 basis points from a year ago. The main driver is expansion in our higher-margin U.S. business, which rose from 22% last year to 35% this year. As you pointed out, the shortfall against our expectations — our original guidance was 71.2% to 72.2% — came mainly from a bigger contribution out of the OUS distributor business; and in terms of that distributor mix, we had planned for roughly 50%. For the quarter, it actually came in at 60% of the OUS business. On a gross profit dollar and revenue dollar basis, that's genuinely favorable, though it does temper our gross margin percentage—which is the effect you're observing this quarter. Regarding the revised guidance for the full year: across the initial nine months, we're running at approximately 70.7%. Since three quarters are now complete, even a better direct-versus-distributor mix in Q4 would only modestly affect our average for the entire year, and that's the reason we've revised our guidance moving forward. The key point is that the fundamental margin drivers remain solid. Both our U.S. business and our minimally invasive business keep expanding. Additional chances for margin improvement are visible to us. Beyond that, geography and channel mix do play a part in how we land, but let me say again that we genuinely see 50 to 100 basis points available going forward.

Anthony Petrone

analyst
#19

Thank you, and congratulations on this quarter. I have a couple of quick questions. Pete, on the implant sizes: you've received FDA clearance for smaller implant sizes, and you're also planning to launch larger platforms. So 90 days ago, how much of the U.S. market was not addressed given where the portfolio stood? With a broader suite of implant sizes now, how much of the U.S. market has actually opened up? Could you also touch on what the funnel of hospitals looks like for reconstruction? How many VAC committee processes do you think you can be involved with right out of the gate following an FDA clearance for reconstruction? Thanks.

Peter Caldini

executive
#20

Thank you, Anthony. Regarding the smaller sizes, for which we recently received approval, we expect those sizes to be on the market by year's end. Historically, we've said this represents about 10% of the market. I believe it opens up a significant opportunity for us in the U.S. market, and it's another driver of utilization across a number of accounts. That's a key driver for us. On the VAC process, one thing to keep in mind is that we're already in about 350 hospitals through the Flora, so that's a good starting point for us. You still have to go through that VAC process; the timeline depends on the individual hospitals. Some can be very quick, some can be shorter, but based on what we've seen in the past, it's anywhere between three to six months. As I mentioned before, we're building out those capabilities so that we're in a position to accelerate through that process. It's not going to be the number of committees; it's going to be more about the timing.

Sandra Harris

executive
#21

Anthony, only to remind you, our Flora tissue expander is now in more than 350 facilities. Although reconstruction on the implants still requires us to go through a VAC process, that remains a really solid beginning given the relationships.

Caitlin Roberts

analyst
#22

Hi there. Thanks a lot for asking the question, and congratulations on the strong quarter. Just to dig a little deeper into recon, are you already preparing your commercial team for the possible expansion in that area? Any thoughts about how competition might shape up as you look at potentially moving into the recon market?

Peter Caldini

executive
#23

Yeah. Thanks, Caitlin. Yeah, we've begun the work of building out our commercial capabilities. As I said earlier, we've raised the number of reps to 55; we'll be doing that through the rest of the year, so we expect that number to grow. We've also set up some of the leadership roles specifically to meet the requirements of the hospital network. Also, some internal capabilities to serve that channel. So we're really making that investment because we see this in the near term.

Analyst

analyst
#24

Morning — Anthony here, filling in for Joanne. Appreciate you taking our question. I just want to follow up on the recon. Thanks for the update on how that process is going. Could you tell us when you expect that approval to come through, and whether those clinical site inspections are the final step, or are there further steps still ahead? Thank you.

Peter Caldini

executive
#25

Yeah. Appreciate the question. To start, I'd say the progress we're making through the recon approval process has us very pleased. It's proceeding as we anticipated. We've supplied the responses to the FDA information request. The BIMO inspections have taken place, and the sponsor site as well. That's a routine part of this process; we can't claim it's finished. We're quite confident we're in a very strong position to secure that approval. The timing of the FDA is never something we can predict. Our confidence is that it will happen in the near term, and our continued belief is that it will be either the end of this year or the start of next. All of it is moving forward as expected, and I think where we stand really shows encouraging signs.

Mason Carrico

analyst
#26

Hi there. Appreciate you giving me the chance to ask. During the recon discussion, you mentioned that Flora is in over 350 facilities at this point. How many hospitals and centers in the U.S. actually do a meaningful volume of implant-based reconstruction? And do you have any sense of what portion of all recon procedures happen at the sites where Flora is already being used today?

Peter Caldini

executive
#27

Yeah. Thanks for asking. When it comes to actual volume and the count of accounts in the U.S., what we're seeing is likely around 130 accounts in the U.S. Flora has helped us get into a number of those accounts, I'd say, though there are still some we can't access until we have the recon indication, since those customers want the full suite of products brought in. Generally speaking, to answer your question, it's roughly 130 accounts — hospital accounts — that account for the majority of the volume.

Anthony Petrone

analyst
#28

Thanks for taking the follow-up. I just have one question about the 25% top-line guide, Sandra, for next year. I'm just wondering how much reconstruction is actually baked into that, or is reconstruction upside to that 25%? Thanks.

Sandra Harris

executive
#29

Yeah, that 25% for 2027 definitely reflects our confidence in the ongoing momentum of our Motiva business, the minimally invasive side, our rising utilization across the U.S., and the market share gains we've discussed. We also view reconstruction as a very important piece of our long-term growth opportunity, and we believe the timing of the regulatory approval stays in line with what we expect — later this year or the first quarter of next year. So our 2027 outlook captures what we expect for our business overall, including the opportunities throughout our portfolio.

Peter Caldini

executive
#30

Yeah. But Anthony, just to build on that point, the VAC process does take somewhat more time than what we've observed with augmentation, which can ramp up very fast right at the start. So as we look at revenue, most of it is going to land in the back half of the year as part of that 25% growth.

Analyst

analyst
#31

Hello, Colin here once more, filling in for Josh. I have a brief follow-up question regarding the international business. Given how strong the distributor performance has been, I am simply wondering if any international demand got pulled forward and whether that had any effect on guidance. Thank you.

Sandra Harris

executive
#32

Yes, Colin, I believe the pattern we observed with our distributors earlier in the year is relevant here, correct? First quarter growth came in at 14.4%. In the second quarter it was 4.4%. Now we have reached 10%. So our confidence in mid-single digit growth for the year remains intact. Within that, we have discussed how the timing of distributor orders always varies in our business. Once again, distributor orders leave us very encouraged. We have additionally been collaborating with our distributors to bring those orders nearer to market demand. We have discussed that, more of a make-to-order program. What we believe, I think, is that it will follow a pattern similar to what it did in the first half of the year.

Mike Matson

analyst
#33

Yes, thank you for taking the follow-up. There's just one point I'd like to raise regarding the NuSil agreement. You referred to some sort of inflationary adjustment in the new agreement. Was anything of that kind present in the earlier agreement? If it wasn't, might this end up creating extra cost tied to inflation? And then perhaps you could give us some context by saying what share of your COGS comes from silicone, since I believe investors have been paying a lot of attention to this, and I'm not convinced it's actually a very large piece of the company's overall cost structure, but.

Sandra Harris

executive
#34

Yes, it's more or less business as usual. Looking at the pricing structure and volume thresholds, it closely mirrors what was in our prior agreement. We expect that pattern to carry on without much disruption. As we've mentioned regarding margins, whenever inflationary pressures arise, we intend to use pricing as a way to help protect those margins. From where we sit, the deal's pricing and volume terms are fairly in line with what we've had before.

Peter Caldini

executive
#35

Yes, thanks, operator, and I appreciate everyone being on the call today. We're really grateful you took the time to be with us, and you're able to see the strong progress the business is making. We're eager for that momentum to carry on as we wrap up 2026, though honestly our focus is on heading into 2027, where we see plenty of opportunities for growth. So we're very glad you can share in that, and we hope to see you at upcoming conferences and earnings calls. Thank you so much.

Operator

operator
#36

Appreciate it, everyone. That brings today's teleconference to a close. You can go ahead and disconnect your lines now, and have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Establishment Labs Holdings Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Establishment Labs Holdings Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Establishment Labs Holdings Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.